Abd-Elmawla, M. A., H. R. ghaiad, Y. A. M. Elbaqy, M. B. Zaki, R. A. Ismail, R. A. El-Shiekh, and E. S. Gad, "Endoplasmic Reticulum Stress and Cellular Dysfunction: Mechanistic Insights into UPR Signaling and Modulation by Natural Products across Diseases", Beni-Suef University Journal of Basic and Applied Sciences, 2026 Jan 10.
Abu-Khudir, R., A. S. Doghish, M. A. Abd-Elmawla, H. R. ghaiad, N. M. Aborehab, M. B. Zaki, H. H. Mohamed, O. A. Mohammed, R. A. B. A. B. S. HAMAD, and H. Elimam, "Cellular Mechanisms and Therapeutic Targeting of Long Non-Coding RNAs in Atherosclerotic Disease", IUBMB Life, 2026 Feb 12.
Hindelah, Y. G., H. R. ghaiad, and T. K. Motawi, "Deferiprone mitigates imidacloprid-induced neurotoxicity: Roles of iron chelation, ferroptosis, and ferritinophagy.", Free radical biology & medicine, vol. 249, pp. 321-335, 2026 Mar 10. Abstract

Imidacloprid (IMI) is a commonly used chloronicotinyl insecticide, although it has low specificity to humans, long-term exposure would induce neurotoxicity through cholinergic signaling disruption and ferroptosis activation. The current investigation aimed to explore the neuroprotective impact of deferiprone (DFP), an iron chelator, against IMI-induced neurotoxicity and whether co-administration with everolimus (EVR), an mTOR inhibitor known to induce autophagy and potentially enhance ferritinophagy, would alter this effect. Adult male Wistar rats were assigned randomly to four different experimental sets: control, IMI, IMI + DFP, and IMI + DFP + EVR groups. They were given IMI (90 mg/kg/day, p.o.), DFP (125 mg/kg/day, p.o.), and EVR (1 mg/kg/day, i.p.) for 30 days. Rats were subjected to neurobehavioral assessments including open-field, rotarod, Y-maze, and tail-immersion tests. Rats' cortices were examined histologically, and acetylcholinesterase (AChE) expression was evaluated immunohistochemically. Several biochemical markers were assessed including oxidative stress markers such as reduced and oxidized glutathione, superoxide dismutase and malondialdehyde, in addition to ferroptotic markers including acyl-CoA synthetase long-chain family member-4, lysophosphatidylcholine acyltransferase-3, iron responsive element binding protein-2, ferritin heavy chain-1, and transferrin receptor-1. IMI administration led to marked biochemical derangements, cortical damage, reduced AChE expression, altered spontaneous motor function, locomotor coordination, spatial memory, and pain threshold while increasing anxious behaviours. DFP ameliorated oxidative stress, reduced ferroptotic markers and alleviated the neurobehavioural defects. Meanwhile, co-administration of EVR abolished these protective effects, consistent with enhanced autophagy-associated iron release and ferroptosis activation. Overall, these findings support the therapeutic potential of DFP against IMI-induced neurotoxicity and highlight ferroptosis as a promising therapeutic target in pesticide-related neurodegeneration.

Doghish, A. S., H. R. ghaiad, N. Elfar, N. H. El Said, A. F. Radwan, M. A. Abd-Elmawla, H. H. Mohamed, O. A. Mohammed, and H. A. Rizk, "Unraveling the Function of lncRNAs in Gliomas: Interaction With Signaling Pathways and Therapeutic Opportunities.", Journal of biochemical and molecular toxicology, vol. 40, issue 3, pp. e70756, 2026 Mar. Abstract

Brain tumors represent some of the most formidable challenges in neuro-oncology due to their aggressive clinical course, resistance to therapy, and profound molecular heterogeneity. Among the emerging regulatory elements reshaping our understanding of tumor biology are long non-coding RNAs (lncRNAs), a diverse class of RNA transcripts that modulate gene expression and cellular behavior without encoding proteins. This review provides an in-depth and integrative examination of the biogenesis, regulatory mechanisms, and functional roles of lncRNAs in brain tumor development and progression. We systematically explore both canonical and non-canonical pathways of lncRNA biogenesis, detailing how these influence structural specificity and molecular interactions. This review synthesized evidence retrieved from PubMed/MEDLINE, Scopus, and Web of Science, covering publications from January 2010 to June 2025. This analysis highlights key gaps, such as context-dependent therapeutic effects that limit translational applicability. A major focus is placed on the interplay between lncRNAs and core oncogenic signaling pathways, including Phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (AKT), Signal Transducer and Activator of Transcription 3 (STAT3), Wingless/Int-1 (Wnt)/β-catenin, and Transforming Growth Factor-Beta (TGF-β), which drive malignant transformation, invasion, stemness, and therapeutic resistance in gliomas. Furthermore, we dissect the molecular functions of lncRNAs as epigenetic regulators, competitive endogenous RNAs (ceRNAs), and structural scaffolds, and discuss their contribution to the dynamic tumor microenvironment. By synthesizing the latest findings, this review underscores the academic and translational importance of targeting lncRNA-associated networks. It also highlights emerging therapeutic approaches, such as antisense oligonucleotides, RNA interference, CRISPR-Cas systems, and natural lncRNA-modulating compounds, which collectively represent a promising frontier in precision medicine for brain tumors. This work offers a critical framework for future research and therapeutic innovation in the lncRNA landscape of neuro-oncology.

Gamil, N. M., H. A. Elsayed, E. T. Salah, H. A. Mostafa, R. A. El-Shiekh, H. R. ghaiad, and H. E. Eitah, "Decoding the mechanistic basis of liver-muscle communication in health and disease.", Naunyn-Schmiedeberg's archives of pharmacology, 2026 Feb 19. Abstract

The bidirectional communication between liver and skeletal muscle represents a critical yet underexplored axis in human physiology. Dysfunction in either organ can accelerate pathology in the other, amplifying disease progression. Understanding this interconnected system is essential for developing targeted and effective therapeutic strategies. This comprehensive review elucidates the complex pathophysiological mechanisms underlying liver-muscle crosstalk and identifies novel therapeutic targets for simultaneous intervention in both organs. We analyzed peer-reviewed literature focusing on molecular pathways, biomarkers, and therapeutic interventions targeting the liver-muscle axis, including cardiac muscle interactions. Key parameters examined included inflammatory mediators (TNF-α, IL-6), metabolic regulators (mTOR, AMPK), hepatokines, myokines, cardiokines, and emerging biomarkers such as zonulin. The liver-muscle axis operates through multiple interconnected pathways: (1) inflammatory cascades where TNF-α inhibits muscle mTOR signaling while promoting hepatic stellate cell activation; (2) metabolic disruption through insulin resistance and AMPK pathway dysfunction affecting both organs simultaneously; (3) gut-liver-muscle crosstalk mediated by microbiome-derived metabolites and intestinal permeability markers like zonulin; (4) hepatokine-myokine signaling networks that coordinate metabolic homeostasis; and (5) liver-heart crosstalk involving cardiomyocyte-hepatocyte interactions through FGF21, IL-6/STAT3 signaling, and inflammatory pathways that distinguish cardiac muscle from skeletal muscle responses. Studying the liver-muscle axis helps in understanding metabolic diseases, transforming them from isolated organ pathologies to interconnected systemic disorders. This framework opens new avenues for precision medicine approaches, biomarker development, and therapeutic innovation that simultaneously optimize liver, skeletal muscle, and cardiac health.

El-Sayed, H. M., K. Hussien, H. R. ghaiad, M. A. Abd-Elmawla, N. M. Abdelmaksoud, A. Ramadan, R. A. El-Shiekh, and M. B. Zaki, "Skeletal Muscle Disorders: Navigating Management and Natural Products.", Chemistry & biodiversity, vol. 23, issue 2, pp. e01803, 2026 Feb. Abstract

Skeletal muscle (SkM) accounts for 30%-40% of body mass. SkM is required for body movement, energy metabolism, and material metabolism, all of which directly impact human quality of life. This review traces the key medicinal plants used for alleviating skeletal muscle disorders (SkMDs), with a focus on lifestyle modifications and exercise. A comprehensive literature search was conducted using databases such as Google Scholar, Elsevier, Springer Nature, Wiley, PubMed, and EKB. SkMDs are a broad category of conditions that affect the muscles, bones, joints, and connective tissues, resulting in major impairments in movement, function, and quality of life. SkMDs affect more than 1.3 billion people worldwide and are a major cause of disability and economic hardship. Conventional therapy approaches, such as pharmaceutical interventions and surgical procedures, are typically limited by undesirable side effects, extended recovery times, and patient dissatisfaction, especially when focusing only on symptom relief. In response, complementary and alternative medicine, particularly medicinal herbs, has grown in popularity to improve SkMD management. Medicinal plants have a diverse range of pharmacologically active compounds with anti-inflammatory, analgesic, and antioxidant effects, making them promising additions to traditional treatments. Berberine, curcumin, resveratrol, quercetin, (-)-epicatechin, and ginsenosides have been reported to have potential in SkMDs. These compounds exert their effects through multiple mechanisms, such as enhancing muscle protein synthesis, reducing inflammation, and modulating hormones that influence muscle mass. Overall, the study emphasizes the ability of natural supplementation approaches to improve clinical outcomes, improve patient well-being, and provide a more sustainable model for treating SkMDs.

ghaiad, H. R., R. A. El-Shiekh, A. M. Atwa, A. M. Mustafa, A. M. Elgindy, M. A. Alkabbani, W. A. Elkady, and K. M. Ibrahim, "From nutrition to therapeutics: the diverse inflammopharmacological and biomedical roles of astaxanthin.", Inflammopharmacology, vol. 34, issue 2, pp. 919-950, 2026 Feb. Abstract

Astaxanthin, a xanthophyll carotenoid derived primarily from Hematococcus lacustris, has been proposed as a potent bioactive compound demonstrating wide therapeutic applicability. In addition to its distinct molecular structure, astaxanthin has exceptional antioxidant property, surpassing that of other carotenoids and conventional antioxidants, while also exerting robust anti-inflammatory effects. The present review focuses on the current evidence of the complex multifaceted therapeutic actions of astaxanthin, including cardiovascular protection, neuroprotection, hepatoprotection, renal support, dermatological health, immune modulation, and emerging roles in metabolic disorders, reproductive health, and cancer prevention. Mechanistic insights highlight its potential to control key molecular mechanisms, including the NF-κB, Nrf2, MAPK, and TGF-β/Smad pathways, alongside the enhancement of endogenous antioxidant defenses. Preclinical and clinical findings have demonstrated benefits in conditions such as atherosclerosis, myocardial ischemia, nonalcoholic fatty liver disease, hypertension, Alzheimer's disease, Parkinson's disease, and inflammatory skin diseases. By integrating evidence drawn from molecular, experimental, and clinical studies, this review underscores astaxanthin's potential as a complementary therapeutic agent and functional nutraceutical. The breadth of its bioactivity positions astaxanthin as a promising natural compound for targeted disease prevention and health promotion.

Elbanna, A. H., A. M. El-Dessouki, S. A. S. Mageed, H. R. ghaiad, S. S. Khalaf, E. S. Gad, K. Abdou, N. M. Aborehab, R. A. El-Shiekh, and S. A. Hamdy, "Natural bioactive compounds and herbal medicines targeting common signaling pathways in endometriosis: mechanisms and therapeutic implications.", Naunyn-Schmiedeberg's archives of pharmacology, 2025 Dec 02. Abstract

For a very long time, herbal treatments have served as remedies for various humans and animals. Natural compounds typically have multiple pharmacological actions because they interact with various biological targets. This characteristic could be exploited to effectively treat disorders with complex physiopathological causes, such as endometriosis. Endometriosis is the proliferation, infiltration, and recurrent bleeding of endometrioid tissue, including stroma and glands, outside the uterine cavity, forming nodules or masses. It affects women of reproductive age and is characterized by persistent inflammation and estrogen dependence, significantly impacting patients' quality of life. Although the precise pathogenic mechanisms remain unclear, current treatments mainly include medication and surgery. Pharmacotherapy typically relies on nonsteroidal anti-inflammatory drugs and hormonal agents, which may cause adverse effects such as gastrointestinal disturbances, hepatic and renal dysfunction, and thrombosis when used as a long-term treatment. Surgical removal of lesions is possible but often followed by recurrence rates of 21.5% after 2 years and up to 50% within 5 years. Therefore, alternative or complementary therapeutic approaches are urgently needed. This review summarizes current evidence on bioactive plant extracts, both crude and refined, and their mechanisms of action against endometriosis, highlighting their multi-target therapeutic potential and underscoring the need for further pre-clinical and clinical studies to develop effective, safer natural treatment strategies.

Habib, S. A., M. M. Kamal, M. H. Aly, H. R. ghaiad, S. M. Rizk, W. A. Banks, and M. A. Erickson, "Streptozotocin Causes Blood-Brain Barrier and Astrocytic Dysfunction In Vitro.", Cells, vol. 14, issue 21, 2025 Nov 06. Abstract

Streptozotocin (STZ) is an alkylating agent that has neurotoxic effects when injected into the cerebral ventricles (ICV) and also models many other features of Alzheimer's disease. However, the mechanisms of STZ neurotoxicity are not well understood. In this study, we hypothesized that some of the neurotoxic effects of STZ could be due to direct activities on brain endothelial cells and astrocytes, which are key in forming and supporting the functions of the blood-brain barrier (BBB), respectively. To test this hypothesis, we characterized the changes induced by STZ either in cultures of human-induced pluripotent stem cell (iPSC)-derived brain endothelial-like cells (iBECs), which form an in vitro BBB model, or in primary human astrocytes. We found that STZ at a dosage of 5 mM caused a delayed reduction in the transendothelial electrical resistance (TEER) of iBECs at 7-11 days post-treatment, indicating induction of BBB leakage. Additionally, we observed significant increases in albumin leakage across the monolayer, altered iBEC morphology, and reductions in tight junction proteins, suggesting that STZ causes BBB disruption. We further found that the BBB glucose transporter GLUT-1 was reduced in iBECs, as was the total number of iBECs. In astrocytes, the 5 mM dose of STZ reduced the GFAP signal and total number of cells, suggesting that STZ has anti-proliferative and/or toxic effects on astrocytes. Together, these data support that STZ's neurotoxic effects could be due, in part, to its direct toxic activities on brain endothelial cells and astrocytes.

Doghish, A. S., M. A. Abd-Elmawla, H. R. ghaiad, N. M. Aborehab, A. F. Radwan, K. Nassar, O. A. Mohammed, and H. Elimam, "Natural Products and LncRNAs in Non-Small Cell Lung Cancer: Emerging Therapeutic Approaches.", The journal of gene medicine, vol. 27, issue 11, pp. e70054, 2025 Nov. Abstract

Non-small cell lung cancer (NSCLC) is considered a major contributor to cancer-related death rates worldwide, chiefly owing to late diagnosis, occurrence of metastasis, and treatment resistance. Growing evidence underscores the impact of long non-coding RNAs (lncRNAs) on NSCLC progression. These lncRNAs have been demonstrated to influence cell proliferation, apoptosis, epithelial-mesenchymal transition (EMT), and drug resistance, contributing to cancer development and therapeutic failure. Concurrently, natural products and nutraceuticals are gaining attention for their anticancer properties, particularly in modulating signaling pathways involved in tumorigenesis and drug resistance. Compounds like curcumin, resveratrol, and epigallocatechin gallate have been shown to regulate oncogenic lncRNAs, inhibiting metastasis and reversing chemoresistance. Additionally, natural products upregulate tumor-suppressive lncRNAs, restoring cell cycle control and apoptosis. This review provides an in-depth analysis of the etiological significance of lncRNAs in NSCLC, with a particular emphasis on their contribution to tumorigenesis, metastasis, and therapeutic resistance. In addition, it explores the potential of natural products to modulate lncRNA expression, highlighting their efficacy in overcoming drug resistance and enhancing the therapeutic response. By elucidating the dynamic molecular cross-talk between lncRNAs and natural products, this review also aims to identify novel therapeutic strategies and potential biomarkers for the diagnosis and treatment of NSCLC.

Tourism